GW Pharmaceuticals
| Public Limited Company | |
| Traded as |
NASDAQ: GWPH : |
| Industry | Pharmaceutical |
| Founded | 1998 |
| Founder | Geoffrey Guy and Brian Whittle |
| Headquarters | Porton Down Science Park, United Kingdom |
|
Key people
|
Justin Gover (CEO) |
| Products | Sativex® |
| Revenue | $33.8 million (2001) |
| Divisions | Biotechnology |
| Website | www |
GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product Sativex, nabiximols (brand name, Sativex). Sativex is the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, for treatment of epilepsy, underwent phase 3 clinical trials in 2015.
Doctors Geoffrey Guy and Brian Whittle founded GW Pharmaceuticals in 1998. That year they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing GW Pharmaceuticals to cultivate cannabis from seeds and clones to conduct scientific research concerning the medicinal uses of the plant.
In July 1998, GW Pharmaceuticals collaborated with HortaPharm B.V., a cannabis research and development business based in the Netherlands, founded by two expert horticulturists from California,Robert Connell Clarke and David Paul Watson, also known as 'Sam the Skunkman'. HortaPharm grew medicinal strains for the Dutch government.
Nabiximols (trade name Sativex) is a botanical drug that is a cannabis extract, administered as a mouth spray; it was approved in the UK in 2010 as a treatment for multiple sclerosis (MS) patients to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.
Nabiximols is made with two unknown Cannabis strains, and is extracted with ethanol and carbon dioxide.
...
Wikipedia